Supportive Care in Cancer
Official Journal of The Multinational Association of Supportive Care In Cancer (MASCC)
Published July 31, 2025
Study Summary:
Results from a multi-center, randomized controlled trial demonstrated the Chemo Mouthpiece® significantly reduces the incidence of chemotherapy induced oral pain and lowers the need for opioids or analgesics, improving patient comfort and treatment adherence.
The trial evaluated the efficacy and tolerability of the Chemo Mouthpiece, a reusable oral cryotherapy device designed to help manage chemotherapy-induced oral mucositis (OM).
The study included 164 adult patients across 16 U.S. sites, randomized 2:1 to receive the Chemo Mouthpiece plus best supportive care (BSC) or BSC alone.
Study Results:
• Patients experienced less pain, used less analgesic pain meds, and used them for less time. Opioid pain medication use was eliminated in the Chemo Mouthpiece arm.
• Participants used the Chemo Mouthpiece starting 10 minutes before chemotherapy, throughout infusion, and at home at least twice daily for five days following infusion.
• Trial included regimens with short and long half-life chemotherapy agents.
• The Chemo Mouthpiece’s portability and ease of use enabled continued at-home use, which was associated with improved efficacy across regimens.
• Of 164 patients: more than 17 cancer types, over 30 different chemotherapies.
• No safety issues associated with use of the device.
PAIN REDUCTION
• 46% Reduction in oral pain episodes vs. control
• During peak symptom days (4–10), device users were pain-free 80% of the time vs. 68% with BSC
OPIOID / ANALGESIC REDUCTION
• 68% Reduction in opioid/analgesic use vs. control
• Use of the Chemo Mouthpiece eliminated opioid use in the per protocol population (Cycle 2)
PATIENT FEEDBACK
• The device was effective, well-tolerated, and provided a convenient way to deliver consistent oral cryotherapy for patients at risk for oral mucositis.
• 83% of patients would recommend the device to others undergoing chemo.
Read the full study in Supportive Care in Cancer
Journal Of The American Dental Association
Published: January 28, 2026
See Case Series Study: Oral mucositis secondary to datopotamab deruxtecan for advanced-stage cancer managed with cryotherapy after topical steroid failure
Summary: Oral mucositis is a clinically meaningful, dose-limiting toxicity commonly seen in Antibody-Drug Conjugate (ADC) therapies. ADC-associated oral mucositis can present early and be debilitating.
A new case study series published in The Journals of the American Dental Association examined patients with TROP2-directed ADC-associated oral mucositis.
This series of cases demonstrated patients treated with this class of ADCs had a favorable outcome with the use of oral cryotherapy, delivered using the Chemo Mouthpiece® medical device.
Read in the Journal Of The American Dental Association
Journal of Comparative Effectiveness Research
Published: February 27, 2026
Summary: A newly published, peer-reviewed economic analysis in the Journal of Comparative Effectiveness Research evaluated the Chemo Mouthpiece® medical device alongside best supportive care and modeled outcomes in a cohort of 1,000 patients receiving chemotherapy. The modeled findings point to meaningful reductions in OM-related burden, including:
- 266 fewer hospital days associated with OM-related complications
- 200 fewer patients requiring analgesics
- 0 (Zero) patients in the Chemo Mouthpiece arm required opioid intervention for pain associated with Oral Mucositis in the clinical trial
- 112 fewer patients requiring medications for infection management
These modeled findings reinforce the broader clinical impact of reducing the incidence and severity of oral mucositis, not only for patient experience, but also for overall care delivery.
The study also evaluated the downstream cost implications in a modeled 1,000-patient cohort. The results estimated:
- Approximately $1,166 in cost savings per patient in the first chemotherapy cycle
- Over $1 million in total cost savings at the cohort level
Reductions in healthcare resource utilization, including hospital length of stay and medication use - In a modeled real-world base case over six chemotherapy cycles, cost savings were estimated at $15,395 per patient
These modeled outcomes were driven by reductions in the incidence and severity of chemotherapy induced oral mucositis and associated complications.
Notably, the analysis suggests that economic benefits may increase across multiple chemotherapy cycles, reflecting the cumulative burden of OM over time.
Read in the Journal of Comparative Effectiveness Research
Journal of Oncology Research and Therapy
Published: April 14, 2025
Study Summary:
A subset analysis of a multi-institutional, randomized controlled study shows that use of the Chemo Mouthpiece® significantly reduced pain and opioid/analgesic use among adult patients receiving chemotherapy for a broad range of cancers.
Key Study Findings:
• 68% reduction in all forms of analgesic use (Chemo Mouthpiece vs. control in the per protocol population).
• 76% reduction in the number of days patients reported using any analgesics for pain (Chemo Mouthpiece vs. control in the per protocol population).
• Use of the Chemo Mouthpiece eliminated opioid use in the per protocol population.
The study provides strong evidence that the Chemo Mouthpiece effectively reduced the need for all forms of analgesics to manage chemotherapy induced oral mucositis associated pain.
Read the full study in Journal of Oncology Research and Therapy
